Literature DB >> 29444938

Intranasal Live Influenza Vaccine Priming Elicits Localized B Cell Responses in Mediastinal Lymph Nodes.

Sinthujan Jegaskanda1,2, Rosemarie D Mason3, Sarah F Andrews3, Adam K Wheatley3,2, Ruijun Zhang4, Glennys V Reynoso5, David R Ambrozak3, Celia P Santos1, Catherine J Luke1, Yumiko Matsuoka1, Jason M Brenchley6, Heather D Hickman5, Kawsar R Talaat7, Sallie R Permar4, Hua-Xin Liao4, Jonathan W Yewdell5, Richard A Koup3, Mario Roederer3, Adrian B McDermott8, Kanta Subbarao9.   

Abstract

Pandemic live attenuated influenza vaccines (pLAIV) prime subjects for a robust neutralizing antibody response upon subsequent administration of a pandemic inactivated subunit vaccine (pISV). However, a difference was not detected in H5-specific memory B cells in the peripheral blood between pLAIV-primed and unprimed subjects prior to pISV boost. To investigate the mechanism underlying pLAIV priming, we vaccinated groups of 12 African green monkeys (AGMs) with H5N1 pISV or pLAIV alone or H5N1 pLAIV followed by pISV and examined immunity systemically and in local draining lymph nodes (LN). The AGM model recapitulated the serologic observations from clinical studies. Interestingly, H5N1 pLAIV induced robust germinal center B cell responses in the mediastinal LN (MLN). Subsequent boosting with H5N1 pISV drove increases in H5-specific B cells in the axillary LN, spleen, and circulation in H5N1 pLAIV-primed animals. Thus, H5N1 pLAIV primes localized B cell responses in the MLN that are recalled systemically following pISV boost. These data provide mechanistic insights for the generation of robust humoral responses via prime-boost vaccination.IMPORTANCE We have previously shown that pandemic live attenuated influenza vaccines (pLAIV) prime for a rapid and robust antibody response on subsequent administration of inactivated subunit vaccine (pISV). This is observed even in individuals who had undetectable antibody (Ab) responses following the initial vaccination. To define the mechanistic basis of pLAIV priming, we turned to a nonhuman primate model and performed a detailed analysis of B cell responses in systemic and local lymphoid tissues following prime-boost vaccination with pLAIV and pISV. We show that the nonhuman primate model recapitulates the serologic observations from clinical studies. Further, we found that pLAIVs induced robust germinal center B cell responses in the mediastinal lymph node. Subsequent boosting with pISV in pLAIV-primed animals resulted in detection of B cells in the axillary lymph nodes, spleen, and peripheral blood. We demonstrate that intranasally administered pLAIV elicits a highly localized germinal center B cell response in the mediastinal lymph node that is rapidly recalled following pISV boost into germinal center reactions at numerous distant immune sites.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  B cells; LAIV; influenza; vaccines

Mesh:

Substances:

Year:  2018        PMID: 29444938      PMCID: PMC5899203          DOI: 10.1128/JVI.01970-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.

Authors:  Irina Isakova-Sivak; Larisa Rudenko
Journal:  Expert Rev Vaccines       Date:  2015-08-06       Impact factor: 5.217

Review 2.  Live attenuated influenza vaccine.

Authors:  Hong Jin; Kanta Subbarao
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

Review 3.  Development of live attenuated influenza vaccines against pandemic influenza strains.

Authors:  Kathleen L Coelingh; Catherine J Luke; Hong Jin; Kawsar R Talaat
Journal:  Expert Rev Vaccines       Date:  2014-05-28       Impact factor: 5.217

4.  A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults.

Authors:  Ruth A Karron; Karen Callahan; Catherine Luke; Bhagvanji Thumar; Josephine McAuliffe; Elizabeth Schappell; Tomy Joseph; Kathleen Coelingh; Hong Jin; George Kemble; Brian R Murphy; Kanta Subbarao
Journal:  J Infect Dis       Date:  2009-03-01       Impact factor: 5.226

5.  An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults.

Authors:  Kawsar R Talaat; Ruth A Karron; Philana H Liang; Bridget A McMahon; Catherine J Luke; Bhagvanji Thumar; Grace L Chen; Ji-Young Min; Elaine W Lamirande; Hong Jin; Kathy L Coelingh; George W Kemble; Kanta Subbarao
Journal:  Influenza Other Respir Viruses       Date:  2012-03-14       Impact factor: 4.380

6.  Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets.

Authors:  Amorsolo L Suguitan; Josephine McAuliffe; Kimberly L Mills; Hong Jin; Greg Duke; Bin Lu; Catherine J Luke; Brian Murphy; David E Swayne; George Kemble; Kanta Subbarao
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

7.  The expression of B & T cell activation markers in children's tonsils following live attenuated influenza vaccine.

Authors:  Jack A Panapasa; Rebecca J Cox; Kristin G I Mohn; Lara A Aqrawi; Karl A Brokstad
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

8.  Lineage structure of the human antibody repertoire in response to influenza vaccination.

Authors:  Ning Jiang; Jiankui He; Joshua A Weinstein; Lolita Penland; Sanae Sasaki; Xiao-Song He; Cornelia L Dekker; Nai-Ying Zheng; Min Huang; Meghan Sullivan; Patrick C Wilson; Harry B Greenberg; Mark M Davis; Daniel S Fisher; Stephen R Quake
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

9.  Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors.

Authors:  Thomas B Kepler
Journal:  F1000Res       Date:  2013-04-03

10.  Evaluation of the Safety and Immunogenicity of a Candidate Pandemic Live Attenuated Influenza Vaccine (pLAIV) Against Influenza A(H7N9).

Authors:  Mahdee Sobhanie; Yumiko Matsuoka; Sinthujan Jegaskanda; Theresa Fitzgerald; Raburn Mallory; Zhongying Chen; Catherine Luke; John Treanor; Kanta Subbarao
Journal:  J Infect Dis       Date:  2015-12-09       Impact factor: 5.226

View more
  14 in total

Review 1.  Extending the Breadth of Influenza Vaccines: Status and Prospects for a Universal Vaccine.

Authors:  Annette Fox; Kylie M Quinn; Kanta Subbarao
Journal:  Drugs       Date:  2018-09       Impact factor: 9.546

2.  Hemagglutinin head-specific responses dominate over stem-specific responses following prime boost with mismatched vaccines.

Authors:  Sinthujan Jegaskanda; Sarah F Andrews; Adam K Wheatley; Jonathan W Yewdell; Adrian B McDermott; Kanta Subbarao
Journal:  JCI Insight       Date:  2019-11-14

3.  How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines.

Authors:  Rajeev Rudraraju; Francesca Mordant; Kanta Subbarao
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

4.  Subdominance and poor intrinsic immunogenicity limit humoral immunity targeting influenza HA stem.

Authors:  Hyon-Xhi Tan; Sinthujan Jegaskanda; Jennifer A Juno; Robyn Esterbauer; Julius Wong; Hannah G Kelly; Yi Liu; Danielle Tilmanis; Aeron C Hurt; Jonathan W Yewdell; Stephen J Kent; Adam K Wheatley
Journal:  J Clin Invest       Date:  2019-01-22       Impact factor: 14.808

5.  Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.

Authors:  Wen-Chun Liu; Raffael Nachbagauer; Daniel Stadlbauer; Alicia Solórzano; Francesco Berlanda-Scorza; Adolfo García-Sastre; Peter Palese; Florian Krammer; Randy A Albrecht
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

Review 6.  Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination.

Authors:  Anna-Karin E Palm; Carole Henry
Journal:  Front Immunol       Date:  2019-07-31       Impact factor: 7.561

7.  Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge.

Authors:  Breanna Hodgins; Stephane Pillet; Nathalie Landry; Brian J Ward
Journal:  Immun Ageing       Date:  2019-11-04       Impact factor: 6.400

Review 8.  Role of Memory B Cells in Hemagglutinin-Specific Antibody Production Following Human Influenza A Virus Infection.

Authors:  Mark Y Sangster; Phuong Q T Nguyen; David J Topham
Journal:  Pathogens       Date:  2019-09-28

9.  Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.

Authors:  David I Bernstein; Jeffrey Guptill; Abdollah Naficy; Raffael Nachbagauer; Francesco Berlanda-Scorza; Jodi Feser; Patrick C Wilson; Alicia Solórzano; Marie Van der Wielen; Emmanuel B Walter; Randy A Albrecht; Kristen N Buschle; Yao-Qing Chen; Carine Claeys; Michelle Dickey; Haley L Dugan; Megan E Ermler; Debra Freeman; Min Gao; Christopher Gast; Jenna J Guthmiller; Rong Hai; Carole Henry; Linda Yu-Ling Lan; Monica McNeal; Anna-Karin E Palm; Dustin G Shaw; Christopher T Stamper; Weina Sun; Victoria Sutton; Micah E Tepora; Rahnuma Wahid; Heather Wenzel; Teddy John Wohlbold; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Lancet Infect Dis       Date:  2019-10-17       Impact factor: 71.421

Review 10.  Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises.

Authors:  Aoife K O'Connell; Florian Douam
Journal:  Vaccines (Basel)       Date:  2020-01-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.